- Zacks Small Cap Research•last year
On November 11, 2015, Immune Pharmaceuticals, Inc. (IMNP) announced financial results for the third quarter of 2015 and provided a business update. This acceptance will enable the company to expand recruitment for the ongoing Phase 2 clinical trial to three planned clinical trial sites in the U.S., including Mount Sinai School of Medicine in New York City.
- Motley Fool•2 years ago
The biotech giant had other options.
- Market Realist•2 years ago
Opko Health (OPK) makes up 1.25% of the SPDR S&P Biotech ETF (XBI). It is a mid-cap stock and has a market cap of ~$6 billion.
RCPT : Summary for Receptos, Inc. - Yahoo Finance